
|Videos|April 4, 2023
Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC
Dr Jason Porter presents safety and efficacy data from a Phase 1/2 study on mobocertinib in patients with mNSCLC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
5




























